Search

… Job Title Lead, Drug Development, MSK Therapeutics Bridge Labs Olivia Vergnolle, PhD, is a Lead Drug Development in the MSK Therapeutics Bridge Labs (TxBL) program, in the Office of Entrepreneurship & Commercialization (OEC). Her responsibilities include protein engineering and bioanalytical characterization

… The Prasad Jallepalli Lab There is a postdoctoral fellow position open in the Jallepalli laboratory.  Applicants with strong interests in cell cycle regulation and chromosome biology, and relevant expertise in genetics, cell biology, biochemistry, and/or chemical biology, should contact the Principal

… Xiong Y, Taleb M, Misawa K, Hou Z, Banerjee S, Amador-Molina A, Jones DR, Chintala NK, Adusumilli PS . c-Kit signaling potentiates CAR T-cell efficacy in solid tumors by CD28- and IL-2–independent costimulation. Nat Cancer . 2023;4(7):1001-1015. [PMID: 37336986] Quach HT, Skovgard MS, Villena-Vargas

… Job Title Fellow Email [email protected]

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

… Wednesday, July 22, 2020 The July 22 MSK Science Spotlight features Luis Diaz, MD , Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.” An accomplished physician, pioneering researcher, and leader in the field

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

… Wednesday, March 8, 2023 You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

… Monday, October 8, 2012 Summary Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells. For the first time, a team of Memorial Sloan Kettering investigators has synthesized erythropoietin (also known as EPO), the hormone

Physician-Scientist and Computational Biologist Joseph M. Chan combines machine learning with single-cell technologies to study lineage plasticity as a mechanism of acquired resistance, immune escape, and metastasis, with a special interest in modeling histological transformation across space, time, and cancer types.

… The Joe Chan Lab combines machine learning with disruptive single-cell sequencing and multiplex spatial imaging to study lineage plasticity in cancer, with a particular focus on histological transformation, as a mechanism of acquired resistance, immune escape, and metastasis. The lab has a special interest

… Job Title MSK Bridge Program Scholar

… 2020 Seminars January 27 Paul Mishcel Form follows function – ecDNA topology drives cancer pathogenesis through altered chromatin organization February 24 Diana Cittelly Estradiol promotes brain metastasis in breast cancer via modulation of the brain niche 2019 Seminars March 25 Michelle Monje Neural